Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) was down 24% on Wednesday . The stock traded as low as C$0.37 and last traded at C$0.38. Approximately 120,484 shares traded hands during mid-day trading, an increase of 1,333% from the average daily volume of 8,405 shares. The stock had previously closed at C$0.50.
Aptose Biosciences Price Performance
The stock has a market capitalization of C$6.70 million, a PE ratio of -0.09 and a beta of 1.36. The business has a fifty day moving average price of C$0.52 and a 200-day moving average price of C$0.86. The company has a current ratio of 0.80, a quick ratio of 5.41 and a debt-to-equity ratio of 670.80.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- Industrial Products Stocks Investing
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Dividend Capture Strategy: What You Need to Know
- Williams-Sonoma Stock: Buy It and Never Let It Go
- 3 Tickers Leading a Meme Stock Revival
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
